<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154011">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094990</url>
  </required_header>
  <id_info>
    <org_study_id>DEX111</org_study_id>
    <secondary_id>PMK111</secondary_id>
    <nct_id>NCT01094990</nct_id>
  </id_info>
  <brief_title>Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy</brief_title>
  <official_title>Efficacy of Dexamethasone for The Prevention of Nausea and Vomiting Associated With Intrathecal Chemotherapy and Ketamine Sedation in Children With Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHANCHAI TRAIVAREE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Null hypothesis The proportions of vomiting are not different between dexamethasone and
      placebo in the patient after sedation with intravenous ketamine and lumbar puncture with
      intrathecal chemotherapy Alternative hypothesis The proportions of vomiting are different
      between dexamethasone and placebo in the patient after sedation with intravenous ketamine
      and lumbar puncture with intrathecal chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Does intravenous dexamethasone 0.25 mg/kg (8 mg/m2/dose) have an effect in the reduction of
      vomiting and retching after sedation with intravenous ketamine and lumbar puncture with
      intrathecal chemotherapy comparison with placebo?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>: To determine whether vomiting and retching associated with intravenous ketamine and intrathecal chemotherapy may be reduced by the addition of prophylactic dexamethasone</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether severity of the nausea after procedure may be reduced by the addition of prophylactic dexamethasone.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Acute Leukemic Patients in Children</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 2-15 years who underlying acute lymphoid or nonlymphoid
             leukemia and need to receive ketamine and intrathecal chemotherapy.

          -  Personally signed and dated informed consent and assent document indicating that the
             subject (or legally acceptable representative) has been informed of all pertinent
             aspects of the trial prior to study entry.

        Exclusion Criteria:

          -  Patients who had a known allergy to ketamine or dexamethasone.

          -  Patients who had contraindication for ketamine or dexemethasone such as hypertension,
             increased intracranial pressure or central nervous system mass lesion, major
             psychiatric , and hyperglycemia.

          -  Patients who concurrent with nausea and vomiting during that time.

          -  Patients who received ondansetron or other antiemetic before doing Procedure.

          -  Patients who received other chemotherapy before or after 24 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chanchai traivaree, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phramongkutklao College of Medicine and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phramongkutklao hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 9, 2012</lastchanged_date>
  <firstreceived_date>March 26, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Phramongkutklao College of Medicine and Hospital</investigator_affiliation>
    <investigator_full_name>CHANCHAI TRAIVAREE</investigator_full_name>
    <investigator_title>Phramongkutklao College of Medicine and Hospital</investigator_title>
  </responsible_party>
  <keyword>crossover; double blinded; intrathecal chemotherapy; dexamethasone; ketamine;vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
